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1. Fluid and sodium restriction for hospitalized patients with decompensated
congestive heart failure provides no significant clinical benefit.
2. Perioperative b-blockers should be given to patients already on them and to
patients who need them for an additional clinical reason (eg, recent myocardial
infarction and heart failure).
3. In patients with atherosclerotic renal artery stenosis, renal artery stenting did
not provide benefit above medical therapy.
4. In patients with diabetic nephropathy, dual angiotensin blockade results in an
increase in adverse drug events without confirmed clinical benefit.
5. Eighth Joint National Committee recommendations include the controversial
recommendation to increase the systolic blood pressure threshold for treat-
ment of adults aged 60 years or older to 150 mm Hg.
6. In patients with an acute exacerbation of chronic obstructive pulmonary
disease, a 5-day course of steroids is as effective as a 14-day course.
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7. In addition to standard resuscitation therapy for inpatients with cardiac arrest,
the combination of vasopressin, steroids, and epinephrine outperformed the
combination of epinephrine and placebo.
8. Checking residual gastric volumes for intubated patients receiving enteral
feeding decreases caloric supplementation without causing a significant effect
on ventilator-associated pneumonia rates.
9. The updated American College of Cardiology Foundation and the American
Heart Association cholesterol guidelines focus on moderate-intensity to
high-intensity statin use for at-risk groups, rather than focusing on target
low-density lipoprotein levels.
10. For patientswith recurrentClostridium difficile infection, duodenal stool infusion
resulted in improvedoutcomeswhencomparedwith vancomycinmonotherapy.INTRODUCTION
The Update in Hospital Medicine is designed to keep readers informed about the cur-
rent state of the literature. For this update, we searched journals from mid-January
2013 to February 2014 and sought high-impact articles that had the capability of prac-
tice change or practice confirmation for hospitalists. Our initial review yielded 577
articles; from this group, a secondary review targeting those with the highest potential
for clinical usefulness yielded 49 articles. From this subgroup, we selected the 10
articles from the year that were most likely to affect patient care.What is the impact of restricting fluid and sodium intake in patients hospital-
ized with an acute systolic heart failure exacerbation?
Aliti GB, Rabelo ER, Clausell N, et al. Aggressive fluid and sodium restriction in
acute decompensated heart failure: a randomized clinical trial. JAMA Intern
Med 2013;173(12):1058–64.Background/Purpose
For patients who are admitted with an acute exacerbation of systolic heart failure, cli-
nicians often limit fluid and sodium intake as a nonpharmacologic measure to improve
congestion and edema. The evidence supporting this practice is limited.
Study Design
The investigators conducted a randomized controlled trial (RCT) comparing a fluid-
restricted (maximum fluid intake, 800 mL/d) and sodium-restricted (maximum sodium
intake, 800 mg/d) diet with no restrictions in patients hospitalized with acute conges-
tive heart failure. The patients enrolled had known systolic heart failure and were diag-
nosed in the emergency department with an acute exacerbation. Patients with chronic
renal failure were excluded.
Results
Over a 3-year period, 75 patients were randomized while in the hospital to a restricted
diet versus a control diet. There were no significant differences between the 2 groups;
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in both groups, and ischemia was the most common cause for the heart failure. There
were no differences between the 2 groups in terms of weight loss or clinical stability
(defined as an improvement in clinical congestion) at 3 days. There were no differ-
ences between the groups with regards to dose of diuretics or overall length of
stay. Patients randomized to the restricted diet reported significantly worse thirst at
the end of the study period (7 days). In addition, at 30-day follow-up, patients in the
restricted diet were more likely to be congested, and there was a nonsignificant trend
toward higher readmissions in the restricted diet group.
Comment
This is a small but well-performed randomized trial of a fluid-restricted and salt-
restricted diet in patients with an acute exacerbation of systolic heart failure, which
showed no clinical benefit of the restricted diet and an increase in patient thirst. The
investigators postulate a few explanations for the findings, including the ability of di-
uretics to manage any increase in fluid intake and that restricting sodium may be
harmful because it can induce antidiuretic and antinatriuretic systems. This study
adds to a few other small studies and raises questions about this practice. Providers
should consider the need to fluid and sodium restrict patients with acute exacerbation
of systolic heart failure and certainly should not restrict to the point of thirst.Given that most of the trials in the DECREASE (Dutch Echocardiographic
Cardiac Risk Evaluation Applying Stress Echocardiography) series have been
discredited, do perioperative b-blockers provide mortality benefits in patients
undergoing noncardiac surgery?
Bouri S, Shun-Shin MJ, Cole GD, et al. Meta-analysis of secure randomised
controlled trials of beta-blockade to prevent perioperative death in non-
cardiac surgery. Heart 2014;100(6):456–64.Background/Purpose
Both the American College of Cardiology Foundation (ACCF) and the American Heart
Association (AHA) and the European Society of Cardiology (ESC) recommend the use
of perioperative b-blockers in certain circumstances. The ESC, as a class I recommen-
dation, encourages the initiation of perioperative b-blockers with dose titration for
patients with established coronary artery disease, ischemia on preoperative stress
testing, or who are undergoing high-risk surgery. The ESC further recommends,
with a class IIa grade, that patients undergoing intermediate-risk surgery should
have b-blockers initiated as well. The ACCF/AHA offer as a class IIa recommendation
that b-blockers be initiated with dose titration in patients undergoing vascular surgery
and who have ischemia on preoperative testing, established coronary artery disease,
or more than 1 risk factor. Furthermore, patients undergoing intermediate-risk surgery
and who have coronary artery disease or more than 1 risk factor should receive dose-
titrated b-blockers. Many of the data for these recommendations rely on a series of
publications from the DECREASE trials. The data and conclusions of most of these tri-
als have been discredited. The goal of this meta-analysis was to analyze the remaining
data from secured trials to determine if the evidence still supports the previously pub-
lished guidelines.
Feldman et ale460Study Design
This meta-analysis included published RCTs comparing noncardiac surgery preoper-
ative b-blocker initiation with placebo in adult patients. The investigators used a sys-
tematic review of databases from 1966 to 2013 and a hand-search of previous
reviews and meta-analyses. Exclusion criteria included studies that did not compare
b-blockers with a placebo treatment, studies in which the b-blockers were given as
a 1-time dose, the DECREASE trials, and studies that did not report intention-to-
treat data. The primary end point was all-cause mortality at 30 days, inclusive of the
in-hospital postoperative period. Nonfatal myocardial infarction (MI), stroke, and hypo-
tension served as secondary end points.
Results
Nine RCTs with 10,529 patients were included in the meta-analysis. b-Blockers
increased the risk of mortality by 27% (relative risk [RR] 1.27, 95% confidence interval
[CI] 1.01%–1.60%, P 5 .04). The absolute risk increase was approximately 0.5% with
a number needed to harm of 200. The 2 DECREASE trials that would have been
included in the meta-analysis had they not been discredited showed a nonstatistically
significant decrease in mortality (RR 0.42, 95% CI 0.15–1.23, P 5 .11). There was a
statistically significant difference between the results from the DECREASE studies
and the 9 secure trials. Although b-blockers significantly decreased the risk of MI
(RR 0.73, 95% CI 0.61–0.88, P 5 .001), the data from the secure trials showed that
b-blockers increased the risk of stroke (RR 1.73, 95% CI 1.00–2.99, P 5 .05) and hy-
potension (RR 1.51, 95% CI 1.37–1.67, P<.00001).
Summary
The discrediting of the DECREASE trials has rocked the perioperative world. Although
large observational trials continue to associate b-blockers with improved outcome in
patients at high risk who are undergoing high-risk procedures, the data from the RCTs
does not support those findings. Although the POISE (Perioperative Ischemic Evalua-
tion) trial dominates this meta-analysis, experts do not agree whether it represents
usual practice. Until further large, multicenter trials are completed, the only patients
who should receive perioperative b-blockers are those who should be treated with
them for other indications (eg, after MI or congestive heart failure) and those who
were receiving b-blockers as a chronic medication before surgery.Does renal artery stenting improve outcomes in patients with renal artery
stenosis?
Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for
atherosclerotic renal-artery stenosis. N Engl J Med 2014;370(1):13–22.Background/Purpose
Renal artery stenosis is a common problem, particularly in elderly patients, and may
result in hypertension or nephropathy. Use of renal artery stenting to treat renal artery
stenosis is common, despite a lack of evidence of benefit. Two randomized trials failed
to show that renal artery stenting benefited kidney function, and 3 randomized trials
failed to show that renal artery angioplasty improved hypertension. But no trials
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events.
Study Design
To determine if renal artery stenting improves outcomes among patients with renal
artery stenosis, the investigators performed a multicenter, open-label, RCT, which
compared medical therapy alone with medical therapy plus renal artery stenting in pa-
tients with atherosclerotic renal artery stenosis and increased blood pressure (BP),
chronic kidney disease, or both. All patients received candesartan, amlodipine, and
atorvastatin (with or without hydrochlorothiazide) titrated to BP and lipid status. Sub-
jects in the stent group also underwent renal artery stenting of 1 or both renal arteries.
The primary end point was the occurrence of a major cardiovascular or renal event
(death from cardiovascular or renal causes, stroke, MI, hospitalization for congestive
heart failure, progressive renal insufficiency, or the need for dialysis).
Results
Stents were placed in 434 of the 459 patients in the stent group (94.6%) and resulted in
a mean reduction of the stenosis from 68% to 16% (P<.001). Arterial dissection was
the most common angiographic complication, occurring in 11 patients (2.5%).
Renal artery stenting did not lead to fewer cardiovascular or renal outcomes. In the
stent group, the primary composite outcome occurred in 35.1% of the patients
compared with 35.8% in the medical therapy group (P 5 .58). In addition, there
were no significant differences between the treatment groups in death from any cause,
stroke, MI, or progressive renal insufficiency. There was no subgroup in which stenting
significantly improved outcomes.
Systolic BP (SBP) was lower in the stent group compared with the medical therapy
group, but the difference was small (–2.3 mmHg, P5 .03) and there was no difference
in the number of antihypertensive medications required in the stent group compared
with the medical therapy group (mean number of antihypertensives: 3.3 vs 3.5,
P 5 .24).
Summary
Renal artery stenting did not provide benefit above medical therapy in patients with
renal artery stenosis and hypertension or chronic kidney disease.Dual angiotensin inhibition with an angiotensin-converting enzyme inhibitor
and an angiotensin II receptor blocker decreases proteinuria, but does it safely
slow the progression of kidney disease?
Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the
treatment of diabetic nephropathy. N Engl J Med 2013;369(20):1892–903.Background/Purpose
Effectively targeting the leading cause of end-stage renal disease (ESRD), diabetic ne-
phropathy, would have important public health implications. Diabetic patients with
proteinuria are at high risk of progressing to ESRD. Decreasing proteinuria through
the use of medications like angiotensin-converting enzyme inhibitors (ACEI) and
angiotensin II receptor blockers (ARB) have improved ESRD outcomes. A previous
study in diabetic patients that treated patients with dual inhibition enrolled subjects
Feldman et ale462with and without overt proteinuria. Results of that study did not favor dual inhibition.
The purpose of this study was to specifically evaluate whether diabetic patients
with overt proteinuria would benefit from dual inhibition.
Study Design
The VA NEPHRON-D (Veterans Affairs Nephropathy in Diabetes) trial pitted treatment
with an ARB alone (losartan) versus dual inhibition with an ARB (losartan) and an ACEI
(lisinopril) in patients with diabetes and albuminuria. The primary outcomes of this
multicenter, double-blind, RCT were the first occurrence of a decline in the estimated
glomerular filtration rate (GFR) (an absolute decrease of 30 mL if estimated GFR was
60 mL at randomization or a relative decrease of 50% if the estimated GFR was
<60 mL at randomization), ESRD, or death. Safety outcomes, including all-cause mor-
tality, serious adverse events, hyperkalemia, and acute kidney injury, were monitored.
The study enrolled veterans with type 2 diabetes who had an estimated GFR of 30.0
to 89.9 mL per minute per 1.73 m2 of body surface area and a urinary albumin/creat-
inine ratio of at least 300 mg/g. Exclusion criteria included known nondiabetic kidney
disease, a serum potassium level greater than 5.5 mg/dL, current treatment with
sodium polystyrene sulfonate, and an inability to stop proscribed medications that
increase potassium.
All patients received 50 mg of losartan per day and had the dose increased to
100 mg per day if potassium levels were less than 5.5 mEq/L and the creatinine did
not increase by greater than 30% from the time of enrollment. After tolerating losartan
for 30 days or more, patients were randomly assigned in a 1:1 ratio to have either
lisinopril or a placebo added to their regimen. The lisinopril or placebo dose was
increased every 2 weeks, from 10 mg to 20 mg to 40 mg per day, if the potassium
levels were less than 5.5 mEq/L and the creatinine did not increase by greater than
30% from the time of randomization.
Results
The 4-year study enrolled 1648 patients and randomized 1448 (724 in each group). A
primary end point occurred more often in patients in the monotherapy group (21%)
compared with the dual therapy group (18.2%), but this difference was not statistically
different. Overall, there was no significant difference in mortality (8.3% vs 8.7%, P 5
.75) or ESRD events (5.9% vs 3.7%, P 5 .07) between the monotherapy versus the
dual therapy groups. Cardiovascular outcomes also did not differ significantly.
Serious adverse events occurred more often in the dual therapy compared with the
monotherapy groups. Acute kidney injury (18.0% vs 11.0%, P<.001) and hyperkalemia
(9.9% vs 4.4%, P<.001) were significantly more prevalent in the dual therapy group.
The study was halted early at the behest of the data and safety monitoring
committee.
Summary
This is likely the last study that will evaluate dual versus monotherapy angiotensin in-
hibition in diabetics. The study was stopped early, even although there was a trend to-
ward improvement in the primary end points and there was a chance that this would
have resulted in a statistically significant improvement if the study had continued as
planned. The data and safety monitoring committee concluded that the risk of serious
adverse events was more likely than the benefit from reducing the primary end point.
Dual angiotensin blockade should not be initiated in type 2 diabetics. If it is started,
patients must be monitored closely for adverse events. Adverse events are likely to
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toring is almost never so close.What are the recommended goals for treating nonacute hypertension? What
are the recommended medications for treating nonacute hypertension?
James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the manage-
mentofhighbloodpressure inadults: report fromthepanelmembers appointed
to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507–20.Background/Purpose
Hypertension is the most common cardiovascular risk factor in the United States. Na-
tional guidelines for managing this condition were last published more than a decade
ago, as the Seventh Joint National Committee (JNC 7) report. This article reports the
recommendations of JNC 8.
Design
Panel members appointed to JNC 8 were selected based on their expertise in hyper-
tension and their background in a variety of disciplines relevant to the care of hyper-
tension. The panel members commissioned external systematic review experts to
search for only RCTs focusing on adults 18 years or older with hypertension, published
between 1966 and 2009. Only trials that enrolled 100 or more patients and reported at
least 1 year of follow-up were included. Panel members supplemented this review with
2 independent searches for major, multicentered RCTs of hypertension that involved
at least 2000 participants and were published from December, 2009 to August, 2013.
Panel members used evidence from these reviews to formulate their recommenda-
tions. Evidence-based recommendations (grade A) required agreement by at least
two-thirds of panel members; those based on expert opinion (grade E) required agree-
ment of at least 75% of panel members.
Recommendations
The JNC 8 panel made 9 recommendations beyond emphasizing healthy diet, weight
control, and physical activity.
Recommendation 1
The panel revised JNC 7 guidelines to recommend that adults 60 years or older be
treated to goal SBP less than 150 mm Hg and goal diastolic BP (DBP) less than
90 mm Hg (grade A). The panel also recommended that patients who have been
treated to SBP less than 140 mm Hg should continue to take their current antihyper-
tensive medications if they are well tolerated.
Recommendations 2 and 3
Unchanged from JNC 7, the panel recommended that adults younger than 60 years be
treated to goal SBP less than 140 mm Hg and DBP less than 90 mm Hg (grade E).
Recommendations 4 and 5
The panel revised JNC 7 guidelines to recommend that both adults with chronic
kidney disease and those with diabetes mellitus be treated to goal SBP less than
140 mm Hg and DBP less than 90 mm Hg (grade E).
Feldman et ale464Recommendations 6, 7, 8, and 9
The JNC 8 panel revised JNC 7 recommendations for prescribing antihypertensive
medications. In a general nonblack population, including those with diabetes, the
panel recommended giving equal preference to the following antihypertensive medi-
cations: thiazide diuretics, calcium channel blockers (CCBs), and ACEIs or ARBs
(grade B). In a general black population, including those with diabetes, it recommends
giving preference to thiazide diuretics or CCBs (grade B and C). In a population with
chronic kidney disease, regardless of race, it recommended including an ACEI or
ARB in the treatment regimen (grade B). The panel recommended that clinicians reas-
sess hypertensive patients monthly until they achieve BP goal. If BP goal is not
achieved, clinicians should add one of the preferred medication classes (avoiding con-
current use of ACEI and ARB), until the patient achieves BP goal or until they have pre-
scribed all 3 classes (thiazide, CCB, and ACEI/ARB) before adding nonpreferred
antihypertensive medications.
Comment
The JNC 8 panel reviewed only high-quality RCTs, in contrast to past JNC panels,
which developed guidelines based on the totality of evidence, including observational
studies, meta-analyses, and expert opinion, as well as RCTs. Its recommendations
(especially the controversial recommendation increasing the SBP threshold for treat-
ment of adults 60 years to 150 mm Hg) have received mixed support. Three panel
members withdrew from authorship before publication, and 5 of the remaining 16
panel members published a separate minority view arguing that absence of RCT ev-
idence for treating to SBP less than 140 mm Hg in older populations is not necessarily
evidence for the absence of benefit.1 National performance standards, such as HEDIS
(Healthcare Effectiveness Data and Information Set) measures, are based on JNC 7
recommendations. Whether JNC 8 will change these standards remains uncertain.Does treating patients with acute exacerbation of chronic obstructive pulmo-
nary disease with a 5-day course of steroids produce similar reexacerbation
rates as treatment for 14 days?
Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorti-
coid therapy in acute exacerbations of chronic obstructive pulmonary disease:
the REDUCE randomized clinical trial. JAMA 2013;309(21):2223–31.Background/Purpose
International guidelines recommend treating acute chronic obstructive pulmonary dis-
ease (COPD) exacerbations with 7 to 14 days of systemic glucocorticoid medications.
However, observational studies and a Cochrane review reported no difference in
clinical outcomes among patients who receive short versus long courses of steroids.
Study Design
The investigators conducted a randomized controlled noninferiority trial of 314 pa-
tients who presented with acute COPD exacerbation to 1 of 5 Swiss teaching hospi-
tals. Patients were randomized to receive a short course (5 days) or a long course
(14 days) of systemic steroids. All patients were treated with 40 mg intravenous meth-
ylprednisolone on the first day and 40 mg oral prednisone on each subsequent day. All
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needed, inhaled glucocorticoids/long-acting b2 agonist twice a day, tiotropium once
daily, and a 7-day course of broad-spectrum antibiotics. Investigators were blinded
to group allocation. Patients were followed for 6 months, and loss to follow-up was
less than 4%. The primary outcome was time to next COPD exacerbation, defined
as an acute clinical deterioration requiring interaction with a clinician.
Results
Patients in the intervention and control groups were well matched at baseline. In
intention-to-treat analysis, 56 patients (35.9%) in the short-term treatment group
and 57 patients (36.8%) in the conventional treatment group experienced COPD reex-
acerbations within 180 days (P value for noninferiority5 .006). Time to reexacerbation
also did not differ between the 2 groups. Among patients who experienced reexacer-
bation, themedian time to event was 43.5 days (interquartile range [IQR], 13–118 days)
in the short-term treatment group and 29 days (IQR, 16–85 days) in the conventional
treatment group. Analysis of prespecified subgroups and secondary end points also
found no significant differences among the treatment groups in terms of glucocorti-
coid use before enrollment, GOLD (Global Initiative for Chronic Obstructive Lung Dis-
ease) classification, FEV1 (forced expiratory volume in first second of expiration)/FVC
(forced vital capacity) change, mortality, incidence of hyperglycemia, or infection
rates. Patients in the short-term treatment group had shorter lengths of stay (median
8 days, IQR 5–11 days vs median 9 days, IQR 6–14 days).
Comment
This high-quality, randomized noninferiority clinical trial shows that a 5-day course
of steroids is equally effective as treating for 14 days for most acute COPD
exacerbations.Can vasopressin and steroids improve outcomes in cardiac arrest resuscitation?
Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopressin, steroids, and
epinephrine and neurologically favorable survival after in-hospital cardiac
arrest: a randomized clinical trial. JAMA 2013;310(3):270–9.Background/Purpose
A pilot study performed in 2009 by the same investigators suggested that vasopressin,
steroids, and epinephrine (VSE) improved survival for hospitalized patients treated for
cardiac arrest when compared with epinephrine and placebo. Unlike the 2005 AHA
guidelines, the 2005 European Resuscitation guidelines did not suggest vasopressin
as an alternative to epinephrine; epinephrine was the preferred first-line agent.
Study Design
The investigators conducted a randomized placebo-controlled double-blind study
from 2008 to 2010 at 3 Greek tertiary-care centers. They enrolled 300 patients who
experienced in-hospital cardiac arrest, excluding 32 who had a return of spontaneous
circulation before medication administration. All remaining patients received care
according to the 2005 European Resuscitation guidelines, but were randomized into
2 groups: the VSE group (20 units of vasopressin with each of the first 5 cycles of
Feldman et ale466cardiopulmonary resuscitation [CPR], along with methylprednisolone 40mg during the
first cycle and a subsequent hydrocortisone taper over 8 days) and the placebo group
(saline without vasopressin or steroids).
Results
Return of spontaneous circulation was significantly improved in the VSE group: 83.9%
versus 65.9% (odds ratio [OR] 2.98, P5 .005). Survival to hospital discharge was simi-
larly improved in the VSE group: 13.9% versus 5.1% (OR 3.28, P5 .02). There was no
significant difference between groups with regard to hospital length of stay, days in the
intensive care unit, or days on the ventilator.
Summary
In addition to standard resuscitation therapy for inpatients with cardiac arrest, the
combination of VSE outperformed the combination of epinephrine and placebo.How will ventilator-associated pneumonia rates be affected if residual gastric
volumes are not monitored for intubated patients receiving nasogastric tube
feeds?
Reignier J, Mercier E, Le Gouge A, et al. Effect of not monitoring residual gastric
volume on risk of ventilator-associated pneumonia in adults receiving mechan-
ical ventilation and early enteral feeding: a randomized controlled trial. JAMA
2013;309(3):249–56.Background/Purpose
For mechanically ventilated patients receiving enteral nutrition, it is common practice
to measure residual gastric volumes in an effort to decrease rates of ventilator-
associated pneumonia (VAP). However, numerous recent studies have suggested
that suspending enteral nutrition in the setting of high residual gastric volumes places
patients at risk for malnutrition without affecting VAP rates. The investigators of the
present study sought to determine the effect of not monitoring residual gastric volume
on VAP rates and on nutrition delivery to the patient.
Study Design
The investigators conducted a randomized multicenter noninferiority trial, in which the
intervention was not to check residual volumes for intubated patients receiving naso-
gastric enteral nutrition. They enrolled 449 patients, excluding patients with expected
duration of intubation of less than 48 hours, previous gastrostomy/jejunostomy, or
gastrointestinal bleeding. Patients in the control group had residual gastric volumes
checked per protocol; these were not checked in the intervention group. In both
groups, enteral feeding was changed in the setting of vomiting; in the control group,
it was also changed for residual gastric volumes higher than 250 cm3.
Results
There was no difference in VAP rate in the intervention (no residual checked) versus
control arm (16.7% vs 15.8%, 90% CI –4.8%–6.7%). Rates of vomiting were
increased in the intervention arm (39.6% vs 27%; P 5 .003), as were rates of
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groups in length of stay or 90-day mortality.
Summary
Clinicians do not need to check residual gastric volumes for intubated patients
receiving enteral feeding, because this practice decreases caloric supplementation
without effecting VAP rates.What is the optimal management of blood cholesterol to reduce atheroscle-
rotic cardiovascular disease risk in adults?
Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the
treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in
adults: a report of the American College of Cardiology/American Heart Associ-
ation task force on practice guidelines. Circulation 2013. [Epub ahead of print].Background/Purpose
There have been numerous RCTs since the last major guidelines on the management
of cholesterol in adults were published in 2002 (Adult Treatment Panel III). This expert
guideline sought to update recommendations for optimal treatment.
Design
An expert panel was convened by the National Heart, Lung, and Blood Institute
(NHLBI) and members reviewed all RCTs, systematic reviews, and meta-analyses
up to 2013 that examined the impact of treatment of blood cholesterol on cardiovas-
cular disease (CVD) risk. All evidence quality was rated according to usual standards.
Initial recommendations were then reviewed by additional experts in the NHLBI as well
as 4 experts nominated by the American College of Cardiology (ACC)/AHA. The guide-
lines were endorsed by the ACC/AHA as well as multiple other national CVD
organizations.
Results/Recommendations
To help clinicians estimate CVD risk, the panel developed the pooled cohort equa-
tions, risk calculators based on 5 large cohorts that allow for CVD risk assessment
that is sex-specific and race-specific as well as including stroke as an outcome.
The expert panel had several key recommendations.
Recommendation 1
The panel endorsed the ACC/AHA Lifestyle Management Guideline,2 which encour-
ages healthy lifestyle habits for all persons, including regular exercise and avoiding
smoking.
Recommendation 2
The benefits of statin therapy outweigh the risks in 4 groups:
1. Those with known CVD (eg, acute MI, stroke, transient ischemic attack) for second-
ary prevention
2. Those with low-density lipoprotein cholesterol (LDL-C) levels of at least 190 mg/dL
for primary prevention
Feldman et ale4683. Those aged 40 to 75 years old with diabetes and LDL-C levels of 70 to 189 mg/dL
for primary prevention
4. Those aged 40 to 75 years old without diabetes and with a 10-year CVD risk of at
least 7.5% (based on the pooled cohort equations) for primary prevention
Note: the investigators did not find evidence to comment on statin use in patients
who receive hemodialysis or have New York Heart Association class II, III, or IV heart
failure.
Recommendation 3
Patients on statins should be monitored for adherence, response to therapy, and
adverse effects within 4 to 12 weeks of initiation or change in statin therapy. Alanine
aminotransferase levels should be checked before initiation; hepatic function and cre-
atine kinase levels should not routinely be monitored but can be checked based on
symptoms.
Recommendation 4
There is an inadequate evidence base to make recommendations for the use of treat-
ment goals to guide therapy; patients should remain on the appropriate statin unless
they have complications. The guidelines also make specific recommendations about
which statin to prescribe for the different scenarios outlined earlier as well as more
specifics regarding response to therapy and side effects.
Comment
These updated cholesterol guidelines were a significant departure from previous
guidelines, which advocated for treating to achieve specific LDL-C goals dependent
on the level of risk. These experts believed that there was inadequate evidence to
advocate for this approach. The specific guidance for the groups in whom the benefits
outweigh the risks should help clinicians make decisions about appropriate therapy.
There has been subsequent controversy since publication of these guidelines
regarding the pooled cohort equations (which determine which patients are included
in group 4), including accusations that they overestimate cardiovascular risk and lead
to overtreatment with statins. The controversy has reached The New York Times.3 Cli-
nicians should be advised that until the calculators are validated, they should be used
cautiously to estimate risk. However, overall, these guidelines were rigorous and well
done and provide clear guidance on optimal cholesterol management.Is duodenal infusion of donor stool efficacious for the treatment of recurrent
Clostridium difficile infection?
van Nood E, Vrieze A, NieuwdorpM, et al. Duodenal infusion of donor feces for
recurrent Clostridium difficile. N Engl J Med 2013;368(5):407–15.Background/Purpose
Recurrent Clostridium difficile infection is common, occurring in 15% to 25% of pa-
tients treated for an initial infection, and antibiotic failure rates for the treatment of
recurrent infection are high. Observational studies of duodenal infusion of feces
from a healthy donor suggest that the treatment is effective. However, RCTs have
not been performed.
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This is an open-label, RCT comparing 3 treatment regimens in patients with recurrent
C difficile infection: (1) vancomycin alone, (2) vancomycin plus bowel lavage, or (3)
abbreviated vancomycin, bowel lavage, and stool infusion. The primary outcome
was cure of infection without relapse within 10 weeks after the initiation of therapy.
Study subjects were patients with a relapse of C difficile infection after at least 1
course of antibiotic therapy. Critically ill patients, patients with immunodeficiency,
and patients who required ongoing treatment with antibiotics for other infections
were excluded. Stool donors were healthy volunteers. Donor stool was screened for
parasites, C difficile, and enteropathogenic bacteria. Donor blood was screened for
human immunodeficiency virus, human T-cell lymphotropic virus, hepatitis A, B,
and C, cytomegalovirus, Epstein-Barr virus, and parasites.
Results
Forty-three patients with median of 3 recurrences ofC difficilewere enrolled in the trial.
The trial was stopped early after an interim analysis reported clear benefit to the stool
infusion group and relapse in most patients in both control groups. In the patients ran-
domized to stool infusion, 81.3% were cured after the first infusion and 93.8% were
cured after a second infusion. In contrast, 30.8% of patients randomized to vancomy-
cin only were cured and 23.1% of patients randomized to vancomycin plus lavage
were cured. Measurements of fecal microbiological diversity were low in patients
before stool infusion and increased significantly to the level of donor diversity after
infusion. After stool infusion, most subjects had diarrhea (94%). In addition, cramping
(31%) and belching (19%) were reported.
Summary
Although this study was small, it represents the strongest evidence to date that treat-
ment with duodenal stool infusion, compared with vancomycin, resulted in better out-
comes in patients with recurrent C difficile infection, including patients with multiple
previous recurrences.
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